tbuckley/cabot-search huggingface dataset:
TCT-251 Impact of Chronic Obstructive Pulmonary Disease on Quality-of-Life Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: Nicole Hoover, Lauren Curtis, Agnieszka Piechota, Susan Erwin, Gary Palardy, Talhat Azemi, Immad Sadiq, Bryan Piccirillo, Robert Hagberg, Mohiuddin Cheema, Francis Kiernan, Raymond McKay
Journal: Journal of the American College of Cardiology (2021)
TCT-323 Is There a Difference in the Types of Complex High-Risk but Indicated Percutaneous Coronary Interventions (CHIP) Undertaken and Their Outcomes Among Different Racial Groups? Insights From a National Cohort
Authors: Warkaa Shamkhani, Tim Kinnaird, Harindra Wijeysundera, Peter Ludman, Muhammad Rashid, Mamas Mamas
Journal: Journal of the American College of Cardiology (2021)
Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
Authors: Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Deepu Madduri, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Yi Lin, Sundar Jagannath
Journal: Blood (2021)
Aberrant cross-talk and expression of β1 integrins and type 1 Insulin-like growth factor receptor during prostate cancer progression.
Authors: Hira L. Goel, Jianzhong Zhang, Ishita Das, Sadie Aznavoorian-Cheshire, Norman M. Greenberg, Ada Elgavish, Lucia R. Languino
Journal: Cancer Research (2005)

310  Cell proliferation responses to growth factor stimulation are significantly altered during cancer progression. To investigate the mechanisms underlying these alterations in prostate cancer, the role and expression of β1A integrin and type 1 insulin-like growth factor receptor (IGF-IR), known to contribute to cell proliferation, were analyzed. Using siRNA oligonucleotides to downregulate β1A, we show that β1A expression is required for IGF-I-stimulated prostate cancer cell proliferation. In vivo, using age-matched TRAMP (transgenic adenocarcinoma of mouse prostate) mice at different stages of prostate cancer [high Prostatic Intraepithelial Neoplasia, PIN; Well-Differentiated, WD, and Poorly-Differentiated, PD, adenocarcinoma], the expression of β1A and of IGF-IR was studied. β1A and IGF-IR expression levels were concurrently upregulated in high PIN and WD prostate cancer, whereas their expression did not correlate in late-stage PD cancer, where low levels of β1A were found. The expression levels of β1C, a β1 cytoplasmic variant, and of Gab1, a β1C integrin downstream effector known to mediate IGF-IR dephosphorylation, were downregulated in all stages of prostate cancer. To analyze in vitro the mechanistic implications of β1A, β1C and Gab1 deregulation, we investigated whether expression of either β1 variants affected IGF-IR localization. We found that IGF-IR and β1A were colocalized in highly specialized integrin signaling compartments, designated focal contacts. However, in the presence of β1C, IGF-IR remained diffuse on the cell surface and did not localize to focal contacts. The findings that β1 integrins and IGF-IR are concurrently deregulated and that β1 integrins modulate IGF-IR intracellular distribution point to the important role that cross-talk between these receptors may have during prostate cancer progression and will be helpful in formulating new therapeutic strategies.
SCIENCE AND FOOD PRODUCTION
Journal: JAMA (1918)

IT WAS far from my intention to suggest that science, generally, had failed to help in increasing the production of food, and least of all to base such an assertion on official statistics of the average yield of wheat. If Sir John Russell had heard Venn's smashing indictment of official underestimating, delivered last year at Oxford, lie would not tilt at that windmill. All I need plead guilty to is extreme sympathy with the view that the value of science is not merely materialistic; but until this sympathy is more universal than it is now, the unenlightened public will not cease to clamour for more spectacular results than agricultural science, in its ‘slow and painful’ progress, has produced in the last fifty years.
TCT-419 Time Course of Ischemic and Bleeding Burden in Consecutive Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: Giuseppe Esposito, Claudio Montalto, Rocco Grippo, Nuccia Morici, Francesco Soriano, Stefano Nava, Federico De Marco, Luca Testa, Francesco Bedogni, Jacopo Oreglia, Gabriele Crimi
Journal: Journal of the American College of Cardiology (2021)
Lectin‐Functionalized Polyethylene Glycol for Relief of Mucosal Dryness
Authors: Matthew Blakeley, Prashant K. Sharma, Hans J. Kaper, Nagihan Bostanci, Thomas Crouzier
Journal: Advanced Healthcare Materials (2021)

The importance of lubrication between oral surfaces provided by the salivary film is most acutely apparent when it is disrupted, a prevalent consequence of salivary gland hypofunction experienced with aging, a symptom of certain diseases, or a side effect of some medical interventions. Sufferers report difficulty with speech and oral food processing and collectively is detrimental to quality of life. Polyethylene glycol (PEG) is widely employed as a successful biocompatible boundary lubricant in engineering and biomedical applications. It is hypothesized that the immobilization of PEG to biological materials such as oral epithelial cells and tissue can mimic the salivary film and provide durable relief from the symptoms of mucosal dryness. To do so, PEG is functionalized with a sugar binding lectin (wheat germ agglutinin) to enhance epithelial adhesion through lectin-sugar interactions. Retention and lubricity are characterized on an ex vivo oral tissue tribology rig. WGA-PEG coats and retains on mucin films, oral epithelial cells, and porcine tongue tissue, and offers sustained reduction in coefficient of friction (COF). WGA-PEG could be developed into a useful topical treatment for reducing oral friction and the perception of dry mouth.
Questions About a Risk Prediction Model of Mortality After Esophagectomy for Cancer
Authors: Alain Braillon
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Comparison of a Pure Plug-Based Versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial
Authors: Mohamed Abdel-Wahab, Philipp Hartung, Oliver Dumpies, Danilo Obradovic, Johannes Wilde, Nicolas Majunke, Peter Boekstegers, Ralf Müller, Melchior Seyfarth, Marc Vorpahl, Philipp Kiefer, Thilo Noack, Sergey Leontyev, Marcus Sandri, Johannes Rotta detto Loria, Mitsunobu Kitamura, Michael Andrew Borger, Anne-Kathrin Funkat, Sven Hohenstein, Steffen Desch, David Holzhey, Holger Thiele
Journal: Circulation (2021)

Transcatheter aortic valve replacement is an established treatment option for patients with severe symptomatic aortic stenosis and is most commonly performed through the transfemoral access route. Percutaneous access site closure can be achieved using dedicated plug-based or suture-based vascular closure device (VCD) strategies, but randomized comparative studies are scarce.The CHOICE-CLOSURE trial (Randomized Comparison of Catheter-based Strategies for Interventional Access Site Closure during Transfemoral Transcatheter Aortic Valve Implantation) is an investigator-initiated, multicenter study, in which patients undergoing transfemoral transcatheter aortic valve replacement were randomly assigned to vascular access site closure using either a pure plug-based technique (MANTA, Teleflex) with no additional VCDs or a primary suture-based technique (ProGlide, Abbott Vascular) potentially complemented by a small plug. The primary end point consisted of access site- or access-related major and minor vascular complications during index hospitalization, defined according to the Valve Academic Research Consortium-2 criteria. Secondary end points included the rate of access site- or access-related bleeding, VCD failure, and time to hemostasis.A total of 516 patients were included and randomly assigned. The mean age of the study population was 80.5±6.1 years, 55.4% were male, 7.6% of patients had peripheral vascular disease, and the mean Society of Thoracic Surgeons score was 4.1±2.9%. The primary end point occurred in 19.4% (50/258) of the pure plug-based group and 12.0% (31/258) of the primary suture-based group (relative risk, 1.61 [95% CI, 1.07-2.44], P=0.029). Access site- or access-related bleeding occurred in 11.6% versus 7.4% (relative risk, 1.58 [95%CI: 0.91-2.73], P=0.133) and device failure in 4.7% versus 5.4% (relative risk, 0.86, [95% CI, 0.40-1.82], P=0.841) in the respective groups. Time to hemostasis was significantly shorter in the pure plug-based group (80 [32-180] versus 240 [174-316] seconds, P<0.001).Among patients treated with transfemoral transcatheter aortic valve replacement, a pure plug-based vascular closure technique using the MANTA VCD is associated with a higher rate of access site- or access-related vascular complications but a shorter time to hemostasis compared with a primary suture-based technique using the ProGlide VCD. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04459208.
Abstract 4491: One-Year Clinical Outcome of a Real World Experience in Patients Treated with a Genous <sup>™</sup> EPC Capturing Stent
Authors: Margo Klomp, Marcel A Beijk, Niels J Verouden, Karel T Koch, José P Henriques, Jan Baan, René J van der Schaaf, Marije M Vis, Jan G Tijssen, Jan J Piek, Robbert J de Winter
Journal: Circulation (2008)

Background Clinical trials of drug-eluting stenting (DES) have demonstrated a marked reduction in the incidence of restenosis compared to bare metal stents. However, concerns have risen regarding the long-term safety of DES. The Endothelial Progenitor Cell (EPC)-capturing stent is coated with an antibody (CD34+) that binds circulating EPCs which differentiate into a functional endothelial layer. This accelerated healing may reduce in-stent restenosis by reducing neointimal hyperplasia and smooth muscle cell proliferation and, in addition, may prevent stent thrombosis(ST). In this single center study, we report the 1-year clinical outcome in patients treated with an EPC-capturing stent. Methods Between September 2005 and March 2007, 257 patients were treated with an EPC-capturing stent for coronary artery stenosis and 236 patients had completed 1-year follow-up. Dual anti-platelet therapy was prescribed for at least 1 month. Results Mean age of the population was 65 years, 72% were male, and 14% were diabetic patients. Three patients had a contra-indication for treatment with a DES, receiving only 2 weeks of clopidogrel post-PCI. A total of 282 lesions were treated of which 252 lesions were treated with an EPC-capturing stent. Of the lesions treated with an EPC-capturing stent, 64% were type B2 or C lesions according to ACC/AHA classification, 16% were CTO and 23% were bifurcated lesions, reflecting daily practice. Mean stent length was 25.13±12.02 mm and mean stent diameter was 3.27±0.36 mm. At 1-year clinical follow-up, 3.0% of the patients died of which 0.8% died from a cardiac cause, and 2.5% of all patients suffered a myocardial infarction. Target vessel revascularization was 9.7% and definite ST was 1.2% (occurring within 24 hours, at 7, and 18 days respectively). At 1-year clinical follow-up the cumulative MACE rate was 11.4%. Conclusion In this single center study, PCI of predominantly complex lesions with a Genous ™ EPC-capturing stent shows excellent 1-year clinical outcomes. Furthermore, using this stent avoids the need for long-term dual anti-platelet therapy.
Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization
Authors: Veronika W. Skrivankova, Rebecca C. Richmond, Benjamin A. R. Woolf, James Yarmolinsky, Neil M. Davies, Sonja A. Swanson, Tyler J. VanderWeele, Julian P. T. Higgins, Nicholas J. Timpson, Niki Dimou, Claudia Langenberg, Robert M. Golub, Elizabeth W. Loder, Valentina Gallo, Anne Tybjaerg-Hansen, George Davey Smith, Matthias Egger, J. Brent Richards
Journal: JAMA (2021)

Mendelian randomization (MR) studies use genetic variation associated with modifiable exposures to assess their possible causal relationship with outcomes and aim to reduce potential bias from confounding and reverse causation.
Providing effective evidence based support for breastfeeding women in primary care
Authors: Joyce Marshall, Sam Ross, Phyll Buchanan, Anna Gavine
Journal: BMJ (2021)

### What you need to know

Baby Kyle was born at term by caesarean section after an uneventful first pregnancy. His birthweight was 3.550 kg and now at 2 weeks old he has regained his birthweight. His mother Ellie has contacted the surgery to make an appointment with the GP and attends a video consultation. Ellie is breastfeeding Kyle and explains she has struggled to access the breastfeeding support she would have liked because of the pandemic. She is concerned Kyle is not getting enough milk. She reports pain when feeding and explains that he has been crying and unsettled after feeds. Ellie has searched online and wonders if Kyle has a cow’s milk protein allergy and she asks if she should exclude dairy from her diet. She is tearful and reports feeling low and isolated. 

The World Health Organization recommends exclusive breastfeeding for six months with continued breastfeeding until 2 years and beyond.12 Breast milk contains many bioactive factors, such as immune factors and cytokines that help …
TCT-276 A Standardized Optical Coherence Tomography Workflow Improves Procedural Efficiency and Safety During Percutaneous Coronary Intervention: Insights From the LightLab Initiative
Authors: Judah Rauch, Michael Johnson, Aziz Maksoud, Daniel Spoon, Frank Zidar, Ethan Korngold, Jana Buccola, Hector Garcia Cabrera, Richard Rapoza, Nick West, Eric Osborn
Journal: Journal of the American College of Cardiology (2021)
Transposition of the great indwelling pleural catheter
Authors: Eihab O Bedawi, Radhika Banka, Fergus V Gleeson, Najib M Rahman, John M Wrightson
Journal: Thorax (2021)

A 70-year-old male with sarcomatoid renal carcinoma presented to his general practitioner with worsening breathlessness. He was referred to the radiology department for a radiograph of the chest, which showed recurrence of a known right malignant pleural effusion (MPE) (figure 1A). After 4 days, he underwent an uncomplicated right indwelling pleural catheter (IPC) insertion and drainage. The postprocedure radiograph of the chest (figure 1B) showed improved appearances of the right MPE and a new small left pleural effusion that had been seen on the preprocedure ultrasound and likely progressed since his presenting radiograph. The radiographer’s report raised concerns that the right IPC tip …
Possibilities of Early Ultrasound Diagnostics of the Herlin — Werner — Wunderlich syndrome (Case Report)
Authors: F. Sh. Mamedova, E. A. Filippova, Z. K. Batyrova, Z. H. Kumykova
Journal: Radiology - Practice (2021)

Herlin — Werner — Wunderlich syndrome or OHVIRA (Obstructed hemivagina and ipsilateral renal anomaly) is a rare type of uterine and vaginal doubling defect (0,1 – 10,0 % of all uterine abnormalities) which is characterized by a triad of symptoms: uterus didelphys, unilateral obstructed hemivagina, and ipsilateral renal dysgenesis. The manifestation of the disease usually present after menarche, is accompanied by severe pain syndrome, leads to redoubted complications and organ-carrying operations with decreasing the fertility. At an earlier age, it can manifest itself as an infection of the genitourinary system. The diagnosis is based on clinical and anamnestic data using instrumental methods, the most accessible and safe of which is ultrasound. This article presents three clinical cases of patients 5 – 6 years old with a description of the ultrasound picture of the OHVIRA syndrome.
TCT-229 Impact of Coronary CT Image Quality on the Accuracy of the FFRCT Planner to Predict Fractional Flow Reserve After PCI
Authors: Daniele Andreini, Martin Penicka, Niya Mileva, Takuya Mizukami, Jeroen Sonck, Bjarne Norgaard, Brian Ko, Hiromasa Otake, Bon-Kwon Koo, Jesper Møller Jensen, Michael Maeng, Sakura Nagumo, Daniel Munhoz, Amy Collinsworth, Adam Updegrove, Jonathon Leipsic, Bernard de Bruyne, Carlos Collet
Journal: Journal of the American College of Cardiology (2021)
Phylogenetic Articulation of Uric Acid Evolution in Mammals and How It Informs a Therapeutic Uricase
Authors: Ze Li, Yosuke Hoshino, Lily Tran, Eric A Gaucher
Journal: Molecular Biology and Evolution (2021)

The role of uric acid during primate evolution has remained elusive ever since it was discovered over 100 years ago that humans have unusually high levels of the small molecule in our serum. It has been difficult to generate a neutral or adaptive explanation in part because the uricase enzyme evolved to become a pseudogene in apes thus masking typical signals of sequence evolution. Adding to the difficulty is a lack of clarity on the functional role of uric acid in apes. One popular hypothesis proposes that uric acid is a potent antioxidant that increased in concentration to compensate for the lack of vitamin C synthesis in primate species ∼65 Ma. Here, we have expanded on our previous work with resurrected ancient uricase proteins to better resolve the reshaping of uricase enzymatic activity prior to ape evolution. Our results suggest that the pivotal death-knell to uricase activity occurred between 20 and 30 Ma despite small sequential modifications to its catalytic efficiency for the tens of millions of years since primates lost their ability to synthesize vitamin C, and thus the two appear uncorrelated. We also use this opportunity to demonstrate how molecular evolution can contribute to biomedicine by presenting ancient uricases to human immune cells that assay for innate reactivity against foreign antigens. A highly stable and highly catalytic ancient uricase is shown to elicit a lower immune response in more human haplotypes than other uricases currently in therapeutic development.
Abstract 11524: Investigation of Pre-procedural Determinants Associated With Resultant No-reflow Phenomenon Following Primary Angioplasty for Acute Myocardial Infraction
Authors: Masanobu Niiyama, Yorihiko Koeda, Tomonori Itoh, Yoshihiro Morino
Journal: Circulation (2019)

Background: The no-reflow phenomenon increases the risk of adverse clinical outcomes during primary percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI). Howe...
Real-World Effectiveness and Immunogenicity of BNT162b2 in Dialysis Patients
Authors: Scott Sibbel, Katherine L. Mckeon, Jiacong Luo, Karl Wendt, Adam G. Walker, Rachael Lazar, Meredith L. Zywno, Jeffrey J. Connaire, Francesca Tentori, Amy Young, Steven M. Brunelli
Journal: Journal of the American Society of Nephrology (2021)

Background: mRNA-1273 (Moderna) is a SARS-CoV-2 vaccine that received an emergency use authorization from the US Food and Drug Administration. Clinical trials in the general population demonstrated that mRNA-1273 reduced risk of COVID-19 by 94.5%, however, dialysis patients were not represented in these trials. Here, we estimated the effectiveness and SARS-CoV-2 antibody response among real-world dialysis patients who were vaccinated with mRNA-1273. Methods: Patients included in this analysis were adults dialyzing at a large dialysis organization. For the effectiveness analysis, patients who began an mRNA-1273 vaccination series (January-March 2021) were matched (with replacement) to up to 3 previously unvaccinated controls based on age, diabetes status, sex, race, body mass index, date of first vaccine, US state of residence, and prior known COVID-19 diagnosis. Vaccine effectiveness was estimated by calculating the hazard ratio (HR) for time to polymerase chain reaction confirmed infection between vaccinated and unvaccinated patients over 3 follow-up intervals: days 1-21, 22-42, and ≥43 after first dose of vaccine. Immunogenicity was measured in a subset of consented patients who completed the full, 2-dose mRNA-1273 vaccination schedule. Blood samples were collected approximately 28 days after the second dose of mRNA-1273, and indirect chemiluminescence immunoassays were used to measure immunoglobulin G (IgG) antibodies against SARS-CoV-2. Samples with a reading of >1 arbitrary unit (AU) were considered IgG+. Results: We identified 23,037 patients who received mRNA-1273 and were matched to 64,243 unvaccinated controls. The HRs and 95% confidence intervals (CI) were 0.96 (0.79, 1.16), 0.51 (0.34, 0.75), and 0.27 (0.17, 0.42) during 1-21, 22-42, and ≥43 days postvaccination, respectively. Among the 329 patients with postvaccination antibody measurements, 96.0% (95% CI: 93.3%-97.9%) were IgG+ (median: 100.5 AU of IgG). Conclusions: Our results indicate that mRNA-1273 is effective in preventing SARSCoV-2 infection in dialysis patients. Moreover, antibodies to SARS-CoV-2 were detected in nearly all patients vaccinated with mRNA-1273 in whom antibodies were measured.
HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160
Authors: Weifeng Liu, Ting-Fang Chou, Sarah C. Garrett-Thomson, Goo-Young Seo, Elena Fedorov, Udupi A. Ramagopal, Jeffrey B. Bonanno, Qingyang Wang, Kenneth Kim, Scott J. Garforth, Kiyokazu Kakugawa, Hilde Cheroutre, Mitchell Kronenberg, Steven C. Almo
Journal: The Journal of Experimental Medicine (2021)

HVEM is a TNF (tumor necrosis factor) receptor contributing to a broad range of immune functions involving diverse cell types. It interacts with a TNF ligand, LIGHT, and immunoglobulin (Ig) superfamily members BTLA and CD160. Assessing the functional impact of HVEM binding to specific ligands in different settings has been complicated by the multiple interactions of HVEM and HVEM binding partners. To dissect the molecular basis for multiple functions, we determined crystal structures that reveal the distinct HVEM surfaces that engage LIGHT or BTLA/CD160, including the human HVEM-LIGHT-CD160 ternary complex, with HVEM interacting simultaneously with both binding partners. Based on these structures, we generated mouse HVEM mutants that selectively recognized either the TNF or Ig ligands in vitro. Knockin mice expressing these muteins maintain expression of all the proteins in the HVEM network, yet they demonstrate selective functions for LIGHT in the clearance of bacteria in the intestine and for the Ig ligands in the amelioration of liver inflammation.